Functional imaging of the salivary glands for evaluation of radiation-induced sialadenitis before and after Lu-177 PSMA radioligand therapy

被引：0
|
作者：
Langbein, T. [1 ]
Kulkarni, H. R. [1 ]
Singh, A. [1 ]
Baum, R. P. [1 ]
机构：
[1] Zent Klin Bad Berka, Bad Berka, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2017年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-587
引用
收藏
页码：S328 / S328
页数：1
相关论文
共 50 条
  • [21] Neuroendocrine differentiation of metastasised castrate-resistant prostate cancer patients referred for radioligand therapy with Lu-177 PSMA
    Grunert, M.
    Miksch, J.
    Steinacker, J.
    Zengerling, F.
    Glatting, G.
    Bolenz, C.
    Beer, A.
    Prasad, V
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 186 - 186
  • [22] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response Reply
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Tripathi, Madhavi
    Bal, Chandrasekhal
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 168 - 169
  • [23] Dosimetric evaluation of the lacrimal glands in patients undergoing therapy with 177Lu-PSMA
    Happel, C.
    Voeller, L.
    Kranert, W. T.
    Groener, D.
    Bockisch, B.
    Ngoc, C. Nguyen
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S102 - S103
  • [24] Hematotoxicity after Radioligand Therapy with 177Lu-PSMA-617 in Patients with Metastastic Prostate Cancer
    Groener, Daniel
    Baumgarten, Justus
    Davis, Karen
    Happel, Christian
    Ngoc, Christina Nguyen
    Wichert, Jennifer
    Mader, Nicolai
    Mandel, Philipp
    Nikolaos, Tselis
    Gruenwald, Frank
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [25] Management of Dry Eye Toxicity After Treatment With 177Lu-PSMA-617 Radioligand Therapy
    Pepin, Abigail
    Lee, Vivian
    O'Brien, Sophia
    Mulugeta, Philipose
    Taunk, Neil K.
    PRACTICAL RADIATION ONCOLOGY, 2024, 14 (04) : 301 - 304
  • [26] Outcomes and prognostic predictors of Lu-177 PSMA radioligand therapy in metastatic castration-resistant prostate cancer (Asian Population Study)
    Chua, Wei Ming
    Lam, Winnie Wing-Chuen
    Tong, Aaron Kian-Ti
    Sultana, Rehena
    Kua, Sandra Mei Yu
    Kanesvaran, Ravindran
    Wong, Alvin Seng Cheong
    Tay, Kae Jack
    Cheng, Tai Jit Lenith
    Ng, David Chee Eng
    Thang, Sue Ping
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 (05) : 572 - 581
  • [27] Clinical outcome of radioligand therapy with Lu-177 PSMA in metastatic prostate cancer: An initial experience from a tertiary care cancer hospital
    Gupta, M.
    Choudhury, P.
    Karthikeyan, G.
    Talwar, V.
    Rawal, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S424 - S425
  • [28] RadioLigand Therapy with [177Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France
    Terroir, Marie
    Lamesa, Chloe
    Krim, Mehdi
    Vija, Lavinia
    Texier, Jean-Sebastien
    Cassou-Mounat, Thibaut
    Delord, Jean-Pierre
    Vallot, Delphine
    Courbon, Frederic
    PHARMACEUTICALS, 2023, 16 (05)
  • [29] 177Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With 177Lu-PSMA-I&T
    Bundschuh, Ralph A.
    Pfob, Christian H.
    Wienand, Georgine
    Dierks, Alexander
    Kircher, Malte
    Lapa, Constantin
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (04) : 337 - 338
  • [30] The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival
    Emine Acar
    Özhan Özdoğan
    Ayşegül Aksu
    Erkan Derebek
    Recep Bekiş
    Gamze Çapa Kaya
    Annals of Nuclear Medicine, 2019, 33 : 681 - 688
12345